Executives
-
Singhal PriyaHead of Development -
Kramer RobinChief Accounting Officer
-
Alexander Susan HEVP Chief Legal Officer
-
Grogan JaneHead of Research
-
Keeney AdamHead of Corporate Development
-
Murphy NicoleHead of Pharm Ops and Tech
-
Gregory GingerEVP, Human Resources
-
Izzar RachidHead of Global Product Strat.
-
Viehbacher ChristopherPresident and CEO
?
Freire Maria C
Director
Biogen Inc.
US, Cambridge [HQ]
CIK
1547999
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
91,007
Price per Share :
$36.20
Equivalence :
$3,294,453.40
Transaction History
-
S91,007 Shares After TransactionValue : $2,417,145.92Sold $219,120.00Transaction Date : 08/14/24
-
Footnotes
-
-
Footnotes:#1 Includes 18,838 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units ("RSUs"). Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock.
-
A4,445 Shares After TransactionValue : $n/a$0.0Transaction Date : 06/21/24
-
Footnotes
-
-
Footnotes:No footnote found.
-
A99,257 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/31/24
-
Footnotes
-
-
Footnotes:#1 Represents restricted stock units ("RSUs") granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The RSUs will vest as to 100% of the shares subject to the RSU award on May 31, 2025, subject to the Reporting Person's continuous service through that date.#2 Includes 39,556 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of RSUs. Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock.